| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
MeBIO targets multiple proteins and pathways. It acts as a potent agonist of the aryl hydrocarbon receptor (AhR), a transcription factor involved in xenobiotic metabolism and immune regulation. It also inhibits GSK-3 and CDK1/cyclin B. Interestingly, it is inactive on GSK-3β, a closely related isoform. Its multi-targeting profile makes it a valuable tool for studying the interplay between these signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, MeBIO demonstrates potent AhR agonist activity. It also shows inhibitory activity against GSK-3 (IC50 = 44 μM) and CDK1/cyclin B (IC50 = 55 μM). Its activity is characterized by its ability to activate AhR-mediated transcription and to modulate GSK-3 and CDK1 activity. This makes it a useful tool for studying the crosstalk between these pathways.
|
| ln Vivo |
In vivo, MeBIO is used in research to study the effects of AhR activation and GSK-3/CDK1 inhibition. While specific in vivo efficacy data are not detailed in the provided sources, its mechanism of modulating multiple signaling pathways makes it a valuable tool for studying various diseases, including cancer and inflammation. Its in vivo effects would depend on the specific model being studied.
|
| Enzyme Assay |
In vitro enzyme/receptor binding studies for MeBIO are not typical, as it acts as a receptor agonist and enzyme inhibitor. Its AhR agonist activity is assessed using reporter assays, where cells are transfected with an AhR-responsive reporter and treated with the compound to measure reporter gene activation. Its inhibition of GSK-3 and CDK1/cyclin B is measured using kinase activity assays.
|
| Cell Assay |
In vitro cellular assays for MeBIO are used to study its effects on cells. Cells are treated with the compound, and key readouts include the activation of AhR target genes (measured by qRT-PCR), the inhibition of GSK-3 and CDK1 activity (measured by Western blotting for phosphorylated substrates), and the effects on cell cycle progression and viability. These assays confirm its mechanism of action.
|
| Animal Protocol |
In vivo animal studies for MeBIO are not extensively documented in the provided sources. As a tool for studying AhR and GSK-3/CDK1 biology, it would be used in animal models of diseases where these pathways are implicated. Such studies would involve administering the compound and measuring relevant endpoints, such as tumor growth, inflammation, or metabolic changes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MeBIO are indicated by its molecular weight of 370.20 g/mol and a molecular formula of C₁₇H₁₂BrN₃O₂. It is a dark red solid. Its solubility and other PK parameters are not detailed in the provided sources. For storage, it is typically kept at -20°C to maintain stability. These properties are important for its use in laboratory studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for MeBIO are limited, as it is a research compound. Its primary value is as a tool for studying signaling pathways. While specific toxicity profiles are not detailed, its mechanism of modulating multiple pathways could have significant effects. Comprehensive safety studies are not available in the public domain.
|
| References | |
| Additional Infomation |
MeBIO is a research-use-only compound that acts as a potent AhR agonist and an inhibitor of GSK-3 and CDK1/cyclin B. Its CAS number is 667463-95-8. It is also known as Me6BIO and 1-Methyl-6-bromo-indirubin-3'-oxime. This compound is a valuable tool for researchers studying the AhR, GSK-3, and CDK1 signaling pathways. It is not an approved drug.
|
| Molecular Formula |
C17H12BRN3O2
|
|---|---|
| Molecular Weight |
370.2
|
| Exact Mass |
369.011
|
| CAS # |
667463-95-8
|
| PubChem CID |
135524908
|
| Appearance |
Brown to reddish brown solid powder
|
| LogP |
1.448
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
23
|
| Complexity |
465
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PIDGGJYETVQYET-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H12BrN3O2/c1-21-13-8-9(18)6-7-11(13)14(17(21)22)16-15(20-23)10-4-2-3-5-12(10)19-16/h2-8,19,22H,1H3
|
| Chemical Name |
6-bromo-1-methyl-3-(3-nitroso-1H-indol-2-yl)indol-2-ol
|
| Synonyms |
Me BIO; Me-BIO; MeBIO
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~14.71 mg/mL (~39.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7012 mL | 13.5062 mL | 27.0124 mL | |
| 5 mM | 0.5402 mL | 2.7012 mL | 5.4025 mL | |
| 10 mM | 0.2701 mL | 1.3506 mL | 2.7012 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
